Nasdaq:US$13.89 (+0.03) | HKEX:HK$22.45 (+0.50) | AIM:£2.07 (+0.01)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 17 Feb 2009

Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn’s Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate

1 items
a090217